MedKoo product information:

 Megestrol Acetate

megestrol acetate is the acetate salt of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone, with progestogenic, antiestrogenic, and antineoplastic activities. Mimicking the action of progesterone, megestrol binds to and activates nuclear progesterone receptors (PRs) in the reproductive system and pituitary; ligand-receptor complexes are translocated to the nucleus where they bind to progesterone response elements (PREs) located on target genes. Megestrol’s antineoplastic activity against estrogen-responsive tumors may be due, in part, to the suppression of pituitary gonadotrophin production and the resultant decrease in ovarian estrogen secretion; interference with the estrogen receptor complex in its interaction with genes and; as part of the progesterone receptor complex, direct interaction with the genome and downregulation of specific estrogen-responsive genes. This agent may also directly kill tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Megestrol is a progesterone derivative with antineoplastic properties used in the treatment of advanced carcinoma of the breast and endometrium. When given in relatively high doses, Megestrol can substantially increase appetite in most individuals, even those with advanced cancer. It is also used to boost appetite in individuals with other cancers or HIV/AIDS. Megestrol acetate oral suspension (a form of Megestrol) is used primarily as an appetite enhancer. The method of appetite enhancement is not known, but it can cause high blood sugar. Currently, it is manufactured under the trade name Megace. Little is known about the drug's chemical interactions. Doses range from 40 mg three times a day, 30 minutes before meals, to 800 mg once a day. Side effects may include diarrhea, rash, and impotence. Males may have some feminizing effects such as gynecomastia (breast development). It is a category X U.S. Food and Drug Administration drug, which means cannot be used in pregnancy as it crosses the placenta and malignantly affects the fetus. See: http://en.wikipedia.org/wiki/Megestrol_acetate.

DRUG DESCRIPTION

Megace® ES (megestrol acetate) oral suspension contains megestrol acetate, a synthetic derivative of the naturally occurring steroid hormone, progesterone. Megestrol acetate is a white, crystalline solid chemically designated as 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate. Solubility at 37° C in water is 2 µg per mL, solubility in plasma is 24 µg per mL. Its molecular weight is 384.52. The chemical formula is C24H32O4.  Megace® ES (megestrol acetate) is a concentrated formula supplied as an oral suspension containing 125 mg of megestrol acetate per mL. Megace® ES (megestrol acetate) oral suspension contains the following inactive ingredients: alcohol (max 0.06% v/v from flavor), artificial lime flavor, citric acid monohydrate, docusate sodium, hydroxypropyl methylcellulose (hypromellose), natural and artificial lemon flavor, purified water, sodium benzoate, sodium citrate dihydrate, and sucrose.

 1: Zang J, Hou M, Gou HF, Qiu M, Wang J, Zhou XJ, Luo DY, Yang Y, Jiang M, Cao D, Bi F, Xu F, Shen Y, Yi C. Antiemetic activity of megestrol acetate in patients receiving chemotherapy. Support Care Cancer. 2010 Apr 26. [Epub ahead of print] PubMed PMID: 20419494.

2: Zarowitz BJ, Tangalos E, Lefkovitz A, Bussey H, Deitelzweig S, Nutescu E, O'Shea T, Resnick B, Wheeler A. Thrombotic risk and immobility in residents of long-term care facilities. J Am Med Dir Assoc. 2010 Mar;11(3):211-21. Epub 2010 Feb 4. PubMed PMID: 20188319.

3: Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr. 2010 Apr;91(4):1143S-1147S. Epub 2010 Feb 17. Review. PubMed PMID: 20164318; PubMed Central PMCID: PMC2844687.

4: Laenen A, Alonso A. The Functional Living Index-Cancer: estimating its reliability based on clinical trial data. Qual Life Res. 2010 Feb;19(1):103-9. PubMed PMID: 20054656.

5: Gibson L, Lawrence D, Dawson C, Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003370. Review. PubMed PMID: 19821307.

6: Garg S, Yoo J, Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review. Support Care Cancer. 2010 Jun;18(6):667-77. Epub 2009 Jul 7. PubMed PMID: 19582484.

7: Gadducci A, Spirito N, Baroni E, Tana R, Genazzani AR. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol. 2009 Oct;25(10):683-91. Review. PubMed PMID: 19562604.

8: Leśniak W, Bała M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome--a systematic review and meta-analysis. Pol Arch Med Wewn. 2008 Nov;118(11):636-44. Review. PubMed PMID: 19140567.

9: Loprinzi CL, Barton DL, Sloan JA, Novotny PJ, Dakhil SR, Verdirame JD, Knutson WH, Kelaghan J, Christensen B. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause. 2008 Jul-Aug;15(4 Pt 1):655-60. PubMed PMID: 18427355.

10: Di Maio M, Daniele B, Pignata S, Gallo C, De Maio E, Morabito A, Piccirillo MC, Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol. 2008 Mar 21;14(11):1682-9. Review. PubMed PMID: 18350599; PubMed Central PMCID: PMC2695908.

11: Megestrol acetate NCD oral suspension--Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2. Drugs R D. 2007;8(6):403-6. PubMed PMID: 17963432.

12: Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2. Drugs R D. 2007;8(4):251-4. Review. Corrected and republished in: Drugs R D. 2007;8(6):403-6. PubMed PMID: 17596111.

13: Melstrom LG, Melstrom KA Jr, Ding XZ, Adrian TE. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol. 2007 Jul;22(7):805-14. Review. PubMed PMID: 17455154.

14: Karagol H, Saip P, Uygun K, Kucucuk S, Aydiner A, Topuz E. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma. Med Oncol. 2006;23(4):543-8. PubMed PMID: 17303913.

15: Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004597. Review. PubMed PMID: 17253515.

16: Gibson LJ, Dawson CK, Lawrence DH, Bliss JM. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD003370. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD003370. PubMed PMID: 17253488.

17: Bertelli G, Paridaens R. Optimal sequence of hormonotherapy in advanced breast cancer. Curr Opin Oncol. 2006 Nov;18(6):572-7. Review. PubMed PMID: 16988577.

18: Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clin Nutr. 2006 Oct;25(5):711-5. Epub 2006 Jul 25. Review. PubMed PMID: 16867306.

19: Milecki P. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers]. Przegl Lek. 2005;62(12):1455-9. Review. Polish. PubMed PMID: 16786772.

20: Cheung KL, Owers R, Robertson JF. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre. Endocr Relat Cancer. 2006 Mar;13(1):251-5. PubMed PMID: 16601292.

21: Marshall LL. Megestrol acetate therapy in geriatric patients: case reviews and associated deep vein thrombosis. Consult Pharm. 2003 Sep;18(9):764-73. PubMed PMID: 16563066.

22: Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther. 2006 Jan;6(1):43-7. Review. PubMed PMID: 16375643.

23: Bodenner DL, Medhi M, Evans WJ, Sullivan DH, Liu H, Lambert CP. Effects of megestrol acetate on pituitary function and end-organ hormone secretion: a post hoc analysis of serum samples from a 12-week study in healthy older men. Am J Geriatr Pharmacother. 2005 Sep;3(3):160-7. PubMed PMID: 16257818.

24: Wong NS, Pritchard KI. A review of exemestane in the management of breast cancer. Expert Opin Pharmacother. 2005 Oct;6(13):2353-63. Review. PubMed PMID: 16218894.

25: Chowdhury S, Ellis PA. Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer. J Br Menopause Soc. 2005 Sep;11(3):96-102. Review. PubMed PMID: 16157000.

26: Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papaldo P, Fabi A, Nisticò C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Terzoli E, Cognetti F. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. Cancer. 2005 Oct 1;104(7):1335-42. Review. PubMed PMID: 16088965.

27: Chetrite GS, Thomas JL, Shields-Botella J, Cortes-Prieto J, Philippe JC, Pasqualini JR. Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues. Anticancer Res. 2005 Jul-Aug;25(4):2827-30. PubMed PMID: 16080533.

28: Cuzick J. Anastrozole. Drugs Today (Barc). 2005 Apr;41(4):227-39. Review. PubMed PMID: 16034487.

29: Mouridsen HT, Bhatnagar AS. Letrozole in the treatment of breast cancer. Expert Opin Pharmacother. 2005 Jul;6(8):1389-99. Review. PubMed PMID: 16013988.

30: Saji S, Toi M. Aromatase inhibitors and other novel agents in breast cancer treatment. Expert Opin Emerg Drugs. 2002 Oct;7(2):303-19. PubMed PMID: 15989553.

31: Ingle JN, Suman VJ. Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):113-9. PubMed PMID: 15939585.

32: Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004310. Review. PubMed PMID: 15846706.

33: André G. [Actions of a 19-norprogesterone derivative on mammary gland: nomegestrol acetate]. J Gynecol Obstet Biol Reprod (Paris). 2005 Feb;34(1 Pt 1):69-84. Review. French. PubMed PMID: 15767920.

34: Shields-Botella J, Chetrite G, Meschi S, Pasqualini JR. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Jan;93(1):1-13. Epub 2005 Jan 26. Review. PubMed PMID: 15748827.

35: Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention. Ann Oncol. 2004 Dec;15(12):1738-47. Review. PubMed PMID: 15550578.

36: Fugate SE, Church CO. Nonestrogen treatment modalities for vasomotor symptoms associated with menopause. Ann Pharmacother. 2004 Sep;38(9):1482-99. Epub 2004 Aug 3. Review. PubMed PMID: 15292498.

37: Simpson D, Curran MP, Perry CM. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs. 2004;64(11):1213-30. Review. PubMed PMID: 15161328.

38: Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? Br J Cancer. 2004 May 4;90(9):1733-9. Review. PubMed PMID: 15150604; PubMed Central PMCID: PMC2410276.

39: Pascual López A, Roqué i Figuls M, Urrútia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, Herdman M. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004 Apr;27(4):360-9. Review. PubMed PMID: 15050664.

40: Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist. 2004;9(2):126-36. Review. PubMed PMID: 15047917.

41: Buzdar AU. Hormonal therapy in early and advanced breast cancer. Breast J. 2004 Jan-Feb;10 Suppl 1:S19-21. Review. PubMed PMID: 14984485.

42: Lønning PE. Exemestane: a review of its clinical efficacy and safety. Breast. 2001 Jun;10(3):198-208. PubMed PMID: 14965585.

43: Herzog TJ. What is the clinical value of adding tamoxifen to progestins in the treatment [correction for treament] of advanced or recurrent endometrial cancer? Gynecol Oncol. 2004 Jan;92(1):1-3. PubMed PMID: 14751129.

44: Howell A, Robertson JF, Vergote I. A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat. 2003 Dec;82(3):215-22. Review. PubMed PMID: 14703069.

45: Mokbel K. Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8. Review. PubMed PMID: 14687437.

46: Jones SE. Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor. Semin Oncol. 2003 Oct;30(5 Suppl 16):14-20. Review. PubMed PMID: 14613022.

47: Brodie AH, Mouridsen HT. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. Am J Clin Oncol. 2003 Aug;26(4):S17-26. Review. PubMed PMID: 12902873.

48: Rose C. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer. Am J Clin Oncol. 2003 Aug;26(4):S9-16. Review. PubMed PMID: 12902872.

49: Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist. 2003;8(4):335-41. Review. PubMed PMID: 12897330.

50: Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D. Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal. J Chemother. 2003 Jun;15(3):220-5. Review. PubMed PMID: 12868546.

51: Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L; Trial 0020 Investigators; Trial 0021 Investigators. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May;79(2):207-11. PubMed PMID: 12825855.

52: Allred DC, Baum M, Buzdar AU, Carlson RW, Dowsett M, Elledge RM, Gradishar WJ, Grana G, Howell A, Mamounas EP. A roundtable discussion of aromatase inhibitors as therapy for breast cancer. Breast J. 2003 May-Jun;9(3):213-22. Review. PubMed PMID: 12752630.

53: Tuca A. [Usefulness of megestrol acetate for weight gain in neoplastic patients with cachexia]. Med Clin (Barc). 2003 May 10;120(17):678; author reply 678. Spanish. PubMed PMID: 12747821.

54: Tamaki Y, Miyoshi Y, Kim SJ, Tanji Y, Taguchi T, Noguchi S. Aromatase inhibitors for treatment of postmenopausal patients with breast cancer. Expert Rev Anticancer Ther. 2003 Apr;3(2):193-201. Review. PubMed PMID: 12722879.

55: Vogel CL. Update on the current use of hormonals as therapy in advanced breast cancer. Anticancer Drugs. 2003 Apr;14(4):265-73. Review. PubMed PMID: 12679730.

56: Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003 Feb;61(2 Suppl 1):32-8. Review. PubMed PMID: 12667885.

57: Pritchard KI. Endocrine therapy of advanced disease: analysis and implications of the existing data. Clin Cancer Res. 2003 Jan;9(1 Pt 2):460S-7S. Review. PubMed PMID: 12538501.

58: Higa GM. Exemestane: treatment of breast cancer with selective inactivation of aromatase. Am J Health Syst Pharm. 2002 Nov 15;59(22):2194-2201; quiz 2202-4. Review. PubMed PMID: 12455303.

59: Ockenga J, Pirlich M, Gastell S, Lochs H. [Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. Z Gastroenterol. 2002 Nov;40(11):929-36. Review. German. PubMed PMID: 12436371.

60: Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol. 2002 Oct;44(1):81-102. Review. PubMed PMID: 12399001.

61: Pasqualini JR, Ebert C. Biological effects of progestins in breast cancer. Gynecol Endocrinol. 1999 Jun;13 Suppl 4:11-9. Review. PubMed PMID: 12227897.

62: Ruiz-García V, Juan O, Pérez Hoyos S, Peiró R, Ramón N, Rosero MA, García MA. [Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia]. Med Clin (Barc). 2002 Jul 6;119(5):166-70. Review. Spanish. PubMed PMID: 12200017.

63: Nabholtz JM, Reese D. Anastrozole in the management of breast cancer. Expert Opin Pharmacother. 2002 Sep;3(9):1329-39. Review. PubMed PMID: 12186625.

64: Dank M. The role of aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res. 2002;8(2):87-92. Review. PubMed PMID: 12172571.

65: Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA, Carney W, Allard JW, Lipton A. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002 Aug;48(8):1314-20. PubMed PMID: 12142389.

66: Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther. 2002;24 Suppl C:C43-57. Review. PubMed PMID: 12117075.

67: Cummings FJ. Evolving uses of hormonal agents for breast cancer therapy. Clin Ther. 2002;24 Suppl C:C3-25. Review. PubMed PMID: 12117074.

68: Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. Clin Ther. 2002;24 Suppl C:C26-42. Review. PubMed PMID: 12117073.

69: Ingle JN. Estrogen as therapy for breast cancer. Breast Cancer Res. 2002;4(4):133-6. Epub 2002 May 15. PubMed PMID: 12100736; PubMed Central PMCID: PMC138731.

70: Dow KH. Existing and emerging endocrine therapies for breast cancer. Cancer Nurs. 2002 Apr;25 Suppl 2:6S-11S. Review. PubMed PMID: 12080538.

71: Crucitta E, Fornier MN, Locopo N, Silvestris N, Lorusso V, De Lena M. Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review). Int J Oncol. 2002 Jun;20(6):1283-8. Review. PubMed PMID: 12012011.

72: Brown JK. A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia. Oncol Nurs Forum. 2002 Apr;29(3):517-32. Review. PubMed PMID: 11979284.

73: Lønning PE. Exemestane in breast cancer: current status and future directions. Clin Breast Cancer. 2000 Sep;1 Suppl 1:S28-33. Review. PubMed PMID: 11970747.

74: Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control. 2002 Mar-Apr;9(2 Suppl):2-8. Review. PubMed PMID: 11965225.

75: Weisberg J, Wanger J, Olson J, Streit B, Fogarty C, Martin T, Casaburi R. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest. 2002 Apr;121(4):1070-8. PubMed PMID: 11948034.

76: Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs. 2002;62(6):957-66. Review. PubMed PMID: 11929341.

77: Pritchard KI. The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. Clin Cancer Res. 2001 Dec;7(12 Suppl):4356s-4359s; discussion 4411s-4412s. Review. PubMed PMID: 11916225.

78: Jones SA, Jones SE. Exemestane: a novel aromatase inactivator for breast cancer. Clin Breast Cancer. 2000 Oct;1(3):211-6. Review. PubMed PMID: 11899645.

79: Lipton A, Ali SM, Leitzel K, Demers L, Chinchilli V, Engle L, Harvey HA, Brady C, Nalin CM, Dugan M, Carney W, Allard J. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002 Mar 15;20(6):1467-72. PubMed PMID: 11896093.

80: Cohen MH, Johnson JR, Li N, Chen G, Pazdur R. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer. Clin Cancer Res. 2002 Mar;8(3):665-9. PubMed PMID: 11895893.

81: Jeffery SM, Pepe JJ, Popovich LM, Vitagliano G. Gabapentin for hot flashes in prostate cancer. Ann Pharmacother. 2002 Mar;36(3):433-6. PubMed PMID: 11895055.

82: Howell A, Howell SJ, Clarke R, Anderson E. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review. PubMed PMID: 11850229.

83: Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):109-14. Review. PubMed PMID: 11850214.

84: Lumley T, Simes RJ, Gebski V, Hudson HM. Combining components of quality of life to increase precision and evaluate trade-offs. Stat Med. 2001 Nov 15;20(21):3231-49. PubMed PMID: 11746315.

85: Mackey JR, Joy AA. Letrozole in second-line therapy of advanced breast cancer: more questions than answers. J Clin Oncol. 2001 Dec 1;19(23):4353-5. PubMed PMID: 11731524.

86: Murray R. Role of anti-aromatase agents in postmenopausal advanced breast cancer. Cancer Chemother Pharmacol. 2001 Oct;48(4):259-65. Review. PubMed PMID: 11710624.

87: Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA, Younger J, Panasci LL, Millard F, Duggan DB, Norton L, Henderson IC; Cancer and Leukemia Group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001 Sep;7(9):2703-11. PubMed PMID: 11555582.

88: Jatoi A, Loprinzi CL. An update: cancer-associated anorexia as a treatment target. Curr Opin Clin Nutr Metab Care. 2001 May;4(3):179-82. Review. PubMed PMID: 11517349.

89: Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001 Jun;28(3):291-304. Review. PubMed PMID: 11402439.

90: Ingle JN. Aromatase inhibition and antiestrogen therapy in early breast cancer treatment and chemoprevention. Oncology (Williston Park). 2001 May;15(5 Suppl 7):28-34. Review. PubMed PMID: 11396362.

91: Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001 Mar;12(3):289-300. Review. PubMed PMID: 11332139.

92: Bonte J. Third generation aromatase inhibitors in metastatic breast cancer patients failing tamoxifen. Randomized comparisons with megestrol acetate: a critical review. Eur J Gynaecol Oncol. 2000;21(6):555-9. Review. PubMed PMID: 11214609.

93: Salvini P, Ripa C, Ginanni V. [Metastatic breast cancer: what are the objectives?]. Tumori. 2000 Sep-Oct;86(5 Suppl 1):S22-8. Review. Italian. PubMed PMID: 11195289.

94: Howell A. Clarification of anastrozole/megestrol acetate trial program design. J Clin Oncol. 2000 Dec 15;18(24):4109. PubMed PMID: 11118472.

95: Dranitsaris G, Leung P, Mather J, Oza A. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs. 2000 Aug;11(7):591-601. PubMed PMID: 11036964.

96: Desport JC, Blanc-Vincent MP, Gory-Delabaere G, Bachmann P, Béal J, Benamouzig R, Colomb V, Kere D, Melchior JC, Nitenberg G, Raynard B, Scheiner S, Senesse P. [Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC)]. Bull Cancer. 2000 Apr;87(4):315-28. French. Erratum in: Bull Cancer 2000 Jun;87(6):490. PubMed PMID: 10827350.

97: Voravud N, Sriuranpong V, Lertsaguansinchai P. Recombinant interferon-alpha 2b and megestrol acetate in patients with advanced renal cell carcinoma. J Med Assoc Thai. 2000 Feb;83(2):123-8. PubMed PMID: 10710880.

98: Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the treatment of postmenopausal breast cancer. Drugs Aging. 1999 Oct;15(4):271-83. Review. PubMed PMID: 10582774.

99: Bernhard J, Thürlimann B, Schmitz SF, Castiglione-Gertsch M, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hürny C. Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol. 1999 Jun;17(6):1672-9. PubMed PMID: 10561203.

100: Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999 Oct;17(10):3299-306. PubMed PMID: 10506633.

101: Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999 May;55(2):189-99. PubMed PMID: 10481946.

102: de Jong PC, Blijham GH. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women. Neth J Med. 1999 Aug;55(2):50-8. Review. PubMed PMID: 10474272.

103: Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol. 1999 Apr;10(4):377-84. Review. PubMed PMID: 10370778.

104: McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer. 1999 Feb;79(3-4):495-500. PubMed PMID: 10027319; PubMed Central PMCID: PMC2362415.

105: Mantovani G, Macciò A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog. 1998;9(2):99-106. Review. PubMed PMID: 9973244.

106: Wiseman LR, Adkins JC. Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging. 1998 Oct;13(4):321-32. Review. PubMed PMID: 9805213.

107: Goss PE. Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor. Breast Cancer Res Treat. 1998;49 Suppl 1:S59-65; discussion S73-7. Review. PubMed PMID: 9797019.

108: Lønning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat. 1998;49 Suppl 1:S53-7; discussion S73-7. Review. PubMed PMID: 9797018.

109: Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998 Oct;16(10):3439-60. Review. PubMed PMID: 9779724.

110: Lønning PE. Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. Br J Cancer. 1998 Sep;78 Suppl 4:12-5. PubMed PMID: 9741783; PubMed Central PMCID: PMC2062757.

111: Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. PubMed PMID: 9740079.

112: Vadell C, Seguí MA, Giménez-Arnau JM, Morales S, Cirera L, Bestit I, Batiste E, Blanco R, Jolis L, Boleda M, Antón I. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol. 1998 Aug;21(4):347-51. PubMed PMID: 9708631.

113: Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol. 1998 Apr;25(2 Suppl 6):104-11. Review. PubMed PMID: 9625392.

114: Chang AY. Megestrol acetate as a biomodulator. Semin Oncol. 1998 Apr;25(2 Suppl 6):58-61. Review. PubMed PMID: 9625385.

115: Smith IE. Pivotal trials of letrozole: a new aromatase inhibitor. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):41-4. Review. PubMed PMID: 9556791.

116: Harvey HA. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):32-5. Review. PubMed PMID: 9556789.

117: Bruera E. Pharmacological treatment of cachexia: any progress? Support Care Cancer. 1998 Mar;6(2):109-13. Review. PubMed PMID: 9540168.

118: Buzdar AU. Anastrozole: a new addition to the armamentarium against advanced breast cancer. Am J Clin Oncol. 1998 Apr;21(2):161-6. Review. PubMed PMID: 9537204.

119: Higa GM, alKhouri N. Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer. Am J Health Syst Pharm. 1998 Mar 1;55(5):445-52. Review. PubMed PMID: 9522927.

120: [ECCO 9 -- Future trends in endocrine therapy of breast cancer]. Tumori. 1997 Sep-Oct;83(5):874-6. Italian. PubMed PMID: 9446251.

121: Leriche N, Bonneterre J. [Progestational agents and bone metastasis in breast cancer]. Bull Cancer. 1997 Sep;84(9):891-4. French. PubMed PMID: 9435812.

122: Harvey HA. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma. Cancer. 1997 Oct 15;80(8 Suppl):1646-51. Review. PubMed PMID: 9362431.

123: Wehbe TW, Stein BS, Akerley WL. Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer. Mayo Clin Proc. 1997 Oct;72(10):932-4. PubMed PMID: 9379696.

124: New aromatase inhibitors for breast cancer. Drug Ther Bull. 1997 Jul;35(7):55-6. Review. PubMed PMID: 9282426.

125: Rubens RD. Aromatase inhibitors for breast cancer--further progress. Eur J Cancer. 1997 Jun;33(7):989-90. PubMed PMID: 9376202.

126: Trunet PF, Vreeland F, Royce C, Chaudri HA, Cooper J, Bhatnagar AS. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. J Steroid Biochem Mol Biol. 1997 Apr;61(3-6):241-5. Review. PubMed PMID: 9365196.

127: Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Olver I, Page J, Abdi E, Wynne C, Friedlander M, Boadle D, Wheeler H, Margrie S, Simes RJ. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol. 1997 Mar;8(3):277-83. PubMed PMID: 9137798.

128: Jonat W. Clinical overview of anastrozole--a new selective oral aromatase inhibitor. Oncology. 1997;54 Suppl 2:15-8. Review. PubMed PMID: 9394855.

129: Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997 Jan-Feb;17(1B):657-62. Review. PubMed PMID: 9066597.

130: Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan;15(1):382-8. Review. PubMed PMID: 8996165.

131: Neifeld JP. Endocrinology of melanoma. Semin Surg Oncol. 1996 Nov-Dec;12(6):402-6. Review. PubMed PMID: 8914204.

132: Stuart NS, Warwick J, Blackledge GR, Spooner D, Keen C, Taylor AR, Tyrell C, Webster DJ, Earl H. A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer. 1996 Oct;32A(11):1888-92. PubMed PMID: 8943670.

133: Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology (Williston Park). 1996 Jul;10(7):1049-56; discussion 1062-4, 1067-8. Review. PubMed PMID: 8837121.

134: Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A, Plourde PV. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996 Jul;14(7):2000-11. PubMed PMID: 8683230.

135: Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, Mulagha M, Cooper J. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer. 1996 Jun 15;77(12):2503-13. PubMed PMID: 8640699.

136: Brawley OW, Cheson BD, Phillips PH. Clinical trials referral resource. Cancer chemoprevention and control trials. Oncology (Williston Park). 1996 Apr;10(4):499-500. PubMed PMID: 8723279.

137: Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol. 1996;35 Suppl 5:15-8. Review. PubMed PMID: 9142959.

138: Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition. 1996 Jan;12(1 Suppl):S43-7. Review. PubMed PMID: 8850220.

139: Freyer G, Catimel G, Merrouche Y. [Synthetic progestational hormones in the treatment of neoplastic cachexia]. Rev Med Interne. 1996;17(1):79-84. Review. French. PubMed PMID: 8677390.

140: Perrone F, Carlomagno C, De Placido S, Lauria R, Morabito A, Bianco AR. First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Ann Oncol. 1995 Dec;6(10):1033-43. Review. PubMed PMID: 8750157.

141: Pasqualini JR, Chetrite G, Nguyen BL, Maloche C, Delalonde L, Talbi M, Feinstein MC, Blacker C, Botella J, Paris J. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):407-12. PubMed PMID: 7626488.

142: Loprinzi CL. Management of cancer anorexia/cachexia. Support Care Cancer. 1995 Mar;3(2):120-2. Review. PubMed PMID: 7773579.

143: Bergman B, Aaronson NK. Quality-of-life and cost-effectiveness assessment in lung cancer. Curr Opin Oncol. 1995 Mar;7(2):138-43. Review. PubMed PMID: 7756378.

144: Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer. 1995 Jan 15;75(2 Suppl):726-34. Review. PubMed PMID: 7805001.

145: Flynn N. Recent results with Megace. J Physicians Assoc AIDS Care. 1995 Jan;2(1):22-3. PubMed PMID: 11362197.

146: van der Vange N, Greggi S, Burger CW, Kenemans P, Vermorken JB. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol. 1995;34(6):813-20. PubMed PMID: 7576750.

147: Espie M. Megestrol acetate in advanced breast carcinoma. Oncology. 1994 Oct;51 Suppl 1:8-12. PubMed PMID: 7970508.

148: Loprinzi CL, Bernath AM, Schaid DJ, Malliard JA, Athmann LM, Michalak JC, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology. 1994 Oct;51 Suppl 1:2-7. PubMed PMID: 7970505.

149: Loprinzi CL, Michalak JC, Quella SK, O'Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994 Aug 11;331(6):347-52. PubMed PMID: 8028614.

150: Vigano A, Watanabe S, Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surv. 1994;21:99-115. Review. PubMed PMID: 8565002.

151: Parazzini F, Colli E, Scatigna M, Tozzi L. Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology. 1993 Nov-Dec;50(6):483-9. Review. PubMed PMID: 8233291.

152: Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol. 1993 Oct;11(10):1957-68. PubMed PMID: 7691999.

153: Tchekmedyian NS. Clinical approaches to nutritional support in cancer. Curr Opin Oncol. 1993 Jul;5(4):633-8. Review. PubMed PMID: 8364079.

154: Tchekmedyian NS. Treatment of anorexia with megestrol acetate. Nutr Clin Pract. 1993 Jun;8(3):115-8. Review. PubMed PMID: 8289758.

155: Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993 Apr;11(4):762-7. PubMed PMID: 8478668.

156: McLeod DG. Antiandrogenic drugs. Cancer. 1993 Feb 1;71(3 Suppl):1046-9. Review. PubMed PMID: 8428326.

157: Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993 Jan;11(1):152-4. PubMed PMID: 8418227.

158: Tchekmedyian NS, Halpert C, Ashley J, Heber D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6 Suppl):88S-92S. Review. PubMed PMID: 1287231.

159: Muss HB, Cruz JM. High-dose progestin therapy for metastatic breast cancer. Ann Oncol. 1992 Aug;3 Suppl 3:15-20. Review. PubMed PMID: 1390312.

160: Loprinzi CL, Goldberg RM, Burnham NL. Cancer-associated anorexia and cachexia. Implications for drug therapy. Drugs. 1992 Apr;43(4):499-506. Review. PubMed PMID: 1377116.

161: Lundgren S. Progestins in breast cancer treatment. A review. Acta Oncol. 1992;31(7):709-22. Review. PubMed PMID: 1476750.

162: Loprinzi CL, Johnson PA, Jensen M. Megestrol acetate for anorexia and cachexia. Oncology. 1992;49 Suppl 2:46-9. PubMed PMID: 1461628.

163: Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology. 1992;49 Suppl 2:35-42. Review. PubMed PMID: 1461626.

164: Abrams JS, Gutheil J, Aisner J. Potential applications of high-dose megestrol acetate in breast cancer. Oncology. 1992;49 Suppl 2:12-7. PubMed PMID: 1461620.

165: Cheson BD. Clinical trials referral resource. Melanoma. Oncology (Williston Park). 1991 Jun;5(6):95, 98, 101. PubMed PMID: 1831644.

166: Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. Semin Oncol. 1991 Feb;18(1 Suppl 2):35-42. PubMed PMID: 1992535.

167: Loprinzi CL, Ellison NM, Goldberg RM, Michalak JC, Burch PA. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin Oncol. 1990 Dec;17(6 Suppl 9):8-12. Review. PubMed PMID: 2259930.

168: Abrams JS, Parnes H, Aisner J. Current status of high-dose progestins in breast cancer. Semin Oncol. 1990 Dec;17(6 Suppl 9):68-72. Review. PubMed PMID: 2148027.

169: Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Overview of hormonal therapy in advanced breast cancer. Semin Oncol. 1990 Dec;17(6 Suppl 9):38-46. PubMed PMID: 2148026.

170: Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, Richards F 2nd, Powell BL, Spurr CL, White D, et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1990 Nov;8(11):1797-805. PubMed PMID: 2230868.

171: Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990 Sep 15;66(6):1279-82. PubMed PMID: 2205358.

172: Patel SR, Kvols LK, Hahn RG, Windschitl H, Levitt R, Therneau T. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer. 1990 Aug 15;66(4):655-8. PubMed PMID: 2201425.

173: Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, Mailliard JA, Johnson PS, Ebbert LP, Geeraerts LH. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990 Jul 4;82(13):1127-32. PubMed PMID: 2193166.

174: Daniel F, MacLeod PM, Tyrrell CJ. Megestrol acetate in relapsed carcinoma of prostate. Br J Urol. 1990 Mar;65(3):275-7. PubMed PMID: 2186841.

175: Willemse PH, van der Ploeg E, Sleijfer DT, Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer. 1990 Mar;26(3):337-43. PubMed PMID: 2141491.

176: Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990 Feb;8(1):61-5. PubMed PMID: 2319292.

177: Lundgren S, Gundersen S, Klepp R, Lønning PE, Lund E, Kvinnsland S. Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat. 1989 Nov;14(2):201-6. PubMed PMID: 2690972.

178: Creagan ET, Ingle JN, Schutt AJ, Schaid DJ. A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol. 1989 Apr;12(2):152-5. PubMed PMID: 2705405.

179: McLeod DG, Murphy GP, Priore R. Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy. Urology. 1988 Nov;32(5):431-6. PubMed PMID: 2973171.

180: Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988 Jul;6(7):1098-106. PubMed PMID: 3292710.

181: Johnson DE, Babaian RJ, Swanson DA, von Eschenbach AC, Wishnow KI, Tenney D. Medical castration using megestrol acetate and minidose estrogen. Urology. 1988 May;31(5):371-4. PubMed PMID: 3284149.

182: Tchekmedyian NS, Tait N, Abrams J, Aisner J. High-dose megestrol acetate in the treatment of advanced breast cancer. Semin Oncol. 1988 Apr;15(2 Suppl 1):44-9. PubMed PMID: 3368800.

183: Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M. Studies of high-dose megestrol acetate: potential applications in cachexia. Semin Oncol. 1988 Apr;15(2 Suppl 1):68-75. Review. PubMed PMID: 3285486.

184: Venner PM, Klotz PG, Klotz LH, Stewart DJ, Davis IR, Orovan WL, Ramsey EW. Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate. Semin Oncol. 1988 Apr;15(2 Suppl 1):62-7. PubMed PMID: 3285485.

185: Sogani PC, Whitmore WF Jr. Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma. Cancer Treat Res. 1988;39:131-45. Review. PubMed PMID: 2908604.

186: Belinson JL, McClure M, Badger G. Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987 Oct;28(2):151-5. PubMed PMID: 3311923.

187: Sogani PC, Fair WR. Treatment of advanced prostatic cancer. Urol Clin North Am. 1987 May;14(2):353-71. Review. PubMed PMID: 2953100.

188: Wander HE, Kleeberg UR, Gärtner E, Hartlapp J, Scherpe A, Bönisch E, Nagel GA. [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study]. Onkologie. 1987 Apr;10(2):104-6. German. PubMed PMID: 2954006.

189: Haller DG, Glick JH. Progestational agents in advanced breast cancer: an overview. Semin Oncol. 1986 Dec;13(4 Suppl 4):2-8. PubMed PMID: 3026051.

190: Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, et al. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec;12(4 Suppl 6):61-4. PubMed PMID: 3909420.

191: Muss HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Stuart JJ, Richards F 2nd, et al. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA). Semin Oncol. 1985 Mar;12(1 Suppl 1):55-61. PubMed PMID: 3883503.

192: Soloway MS. Newer methods of hormonal therapy for prostate cancer. Urology. 1984 Nov;24(5 Suppl):30-8. PubMed PMID: 6437034.

193: Alexieva-Figusch J, Teulings FA, Hop WC, Blonk-van der Wijst J, van Gilse HA. Steroid receptors in megestrol acetate therapy. Recent Results Cancer Res. 1984;91:253-8. PubMed PMID: 6203149.

194: Blumenschein GR. The role of progestins in the treatment of breast cancer. Semin Oncol. 1983 Dec;10(4 Suppl 4):7-10. PubMed PMID: 6230722.

195: Canetta R, Florentine S, Hunter H, Lenaz L. Megestrol acetate. Cancer Treat Rev. 1983 Sep;10(3):141-57. Review. PubMed PMID: 6352021.

196: Ansfield FJ, Kallas GJ, Singson JP. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast. Surg Gynecol Obstet. 1982 Dec;155(6):888-90. PubMed PMID: 7147170.

197: Montie JE, Bukowski RM, James RE, Straffon RA, Stewart BH. A critical review of immunotherapy of disseminated renal adenocarcinoma. J Surg Oncol. 1982 Sep;21(1):5-8. PubMed PMID: 7109637.

198: Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Creagan ET, Hahn RG, Rubin J. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol. 1982 Apr;5(2):155-60. PubMed PMID: 7046412.

199: Geller J, Albert J, Yen SS, Geller S, Loza D. Medical castration of males with megestrol acetate and small doses of diethylstilbestrol. J Clin Endocrinol Metab. 1981 Mar;52(3):576-80. PubMed PMID: 6161942.

200: Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep. 1979 Mar;63(3):513-5. PubMed PMID: 371804.

201: Bishun N, Mills J, Parke JV, Williams DC. A cytogenetic study in women who had used oral contraceptives and in their progeny. Mutat Res. 1975 Dec;33(2-3):299-310. PubMed PMID: 765801.